EA202191800A1 - Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак - Google Patents

Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак

Info

Publication number
EA202191800A1
EA202191800A1 EA202191800A EA202191800A EA202191800A1 EA 202191800 A1 EA202191800 A1 EA 202191800A1 EA 202191800 A EA202191800 A EA 202191800A EA 202191800 A EA202191800 A EA 202191800A EA 202191800 A1 EA202191800 A1 EA 202191800A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
cancer
azheterobyclic
targeting
application
Prior art date
Application number
EA202191800A
Other languages
English (en)
Inventor
Зенон Д. Контеатис
Минцзун Ли
Сэмюэл К. Резник
Чжихуа Суй
Джереми М. Трэвинс
Original Assignee
Ле Лаборатуар Сервье Сас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье Сас filed Critical Ле Лаборатуар Сервье Сас
Publication of EA202191800A1 publication Critical patent/EA202191800A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к соединениям формулы (I), формулы (II) и их фармацевтически приемлемым солям, таутомерам и/или изотопологам, раскрытым в описании. Соединения являются ингибиторами изоформы 2A метионин-аденозилтрансферазы (MAT2A). Также представлены фармацевтические композиции и способы применения соединений для лечения рака, включая некоторые виды рака с удаленным геном, кодирующим метилтиоаденозинфосфорилазу (MTAP).
EA202191800A 2018-12-27 2019-12-27 Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак EA202191800A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785574P 2018-12-27 2018-12-27
PCT/US2019/068653 WO2020139992A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
EA202191800A1 true EA202191800A1 (ru) 2021-09-13

Family

ID=69400626

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191800A EA202191800A1 (ru) 2018-12-27 2019-12-27 Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак

Country Status (21)

Country Link
US (1) US20220098203A1 (ru)
EP (1) EP3902804A1 (ru)
JP (1) JP2022516882A (ru)
KR (1) KR20220050832A (ru)
CN (1) CN113474347A (ru)
AR (1) AR115296A1 (ru)
AU (1) AU2019414446A1 (ru)
BR (1) BR112021012599A2 (ru)
CA (1) CA3124678A1 (ru)
CL (1) CL2021001722A1 (ru)
CO (1) CO2021009882A2 (ru)
CR (1) CR20210409A (ru)
EA (1) EA202191800A1 (ru)
IL (1) IL284324A (ru)
JO (1) JOP20210171A1 (ru)
MA (1) MA54609A (ru)
MX (1) MX2021007833A (ru)
PE (1) PE20212303A1 (ru)
SG (1) SG11202106627WA (ru)
TW (1) TW202039489A (ru)
WO (1) WO2020139992A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105469YA (en) 2018-12-10 2021-06-29 Ideaya Biosciences Inc 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
CA3177164A1 (en) * 2020-04-28 2021-11-04 Peter Sennhenn Bicyclic kinase inhibitors and uses thereof
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
JP2024502097A (ja) * 2020-12-31 2024-01-17 南京再明医薬有限公司 三環式化合物とその用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
TW202333696A (zh) * 2022-01-26 2023-09-01 大陸商勤浩醫藥(蘇州)有限公司 用於治療ｍｔａｐ缺失型癌症的甲硫氨酸腺苷轉移酶２ａ抑制劑
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2024080788A1 (ko) 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2000024744A1 (en) * 1998-10-23 2000-05-04 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
ATE353329T1 (de) * 1999-10-21 2007-02-15 Hoffmann La Roche Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
EP1615928A1 (en) * 2003-04-10 2006-01-18 F.Hoffmann-La Roche Ag Pyrimido compounds
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
AU2017319500C1 (en) * 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
CN109384790B (zh) * 2017-08-08 2022-05-10 药捷安康(南京)科技股份有限公司 成纤维细胞生长因子受体抑制剂及其用途
CN111936499B (zh) * 2018-03-30 2023-09-19 法国施维雅药厂 Mat2a的杂二环抑制剂和用于治疗癌症的方法

Also Published As

Publication number Publication date
MA54609A (fr) 2022-04-06
EP3902804A1 (en) 2021-11-03
KR20220050832A (ko) 2022-04-25
SG11202106627WA (en) 2021-07-29
BR112021012599A2 (pt) 2021-09-08
AU2019414446A1 (en) 2021-07-15
US20220098203A1 (en) 2022-03-31
MX2021007833A (es) 2021-10-26
CO2021009882A2 (es) 2021-10-29
AR115296A1 (es) 2020-12-16
CR20210409A (es) 2022-01-24
TW202039489A (zh) 2020-11-01
JP2022516882A (ja) 2022-03-03
CN113474347A (zh) 2021-10-01
WO2020139992A1 (en) 2020-07-02
JOP20210171A1 (ar) 2023-01-30
CL2021001722A1 (es) 2022-02-18
PE20212303A1 (es) 2021-12-10
IL284324A (en) 2021-08-31
CA3124678A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
EA202191800A1 (ru) Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
PH12020551305A1 (en) Pharmaceutical Compounds
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023008994A (es) Derivados de pirazina fusionados como inhibidores de a2a/a2b.
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA202190458A1 (ru) Составы, содержащие дендример
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
EA202192382A1 (ru) Соединения, нацеленные на prmt5
EA202190204A1 (ru) Производные конденсированных пиразинов как ингибиторы a2a/a2b
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ